Arkin Bio Ventures, a division of Arkin Holdings based in Herzliya, Israel, was founded with the mission to empower companies developing breakthrough pharma, biotech, and medical device technologies. The firm focuses on identifying, investing in, and supporting early to mid-stage companies with innovative solutions in areas such as immunotherapy, cancer, metabolism, microbiome, CNS, autoimmune diseases, orphan diseases, and drug delivery platforms. Their core vision is to advance these groundbreaking technologies from the development stage to proof of concept and beyond.

Notable figures affiliated with Arkin Bio Ventures include its experienced management team, which plays a crucial role in guiding portfolio companies through the complexities of drug development. The firm has garnered significant attention and investment from key players in the healthcare and biotech sectors. Arkin Bio Ventures has achieved considerable success by fostering innovations that have the potential to transform patient care and treatment paradigms, thereby making a substantial impact on the global healthcare landscape.